Lushang Furuida Pharmaceutical Co., Ltd. (stock code: 600223) is a pharmaceutical and cosmetics group with medicine and cosmetics as its core business, combining production, education and research, and integrating science, industry and trade. It is the creator of China's hyaluronic acid industry. The leader, whose industries are involved in raw materials, drugs, medical devices, health food, food, cosmetics, etc.

The company has always adhered to innovation and development, with market demand as the core and product innovation as the leader, invested 100 million to 200 million R&D funds every year, established a R&D team of more than 360 people, and established four national-level enterprises, including the National Enterprise Technology Center, Academician Workstation, and 15 provincial platforms have established long-term and stable cooperative relations with well-known universities and research institutes such as Zhejiang University and the Shanghai Institute of Pharmaceuticals of the Chinese Academy of Sciences. They have successively undertaken more than 30 major national and provincial scientific and technological projects at the national and ministerial levels and have been authorized 270 patents.

There are seven production bases in Jinan, Linyi, Jining, Yining, Xinjiang, etc., including biofermentation raw materials, plant extraction raw materials, chemical synthetic raw materials, pharmaceutical preparations, skin and fragrance care and cosmetics. Established a quality assurance system that is in line with international quality supervision concepts such as ICH, FDA, EDQM, PMDA, etc. All preparations and varieties have passed the national new version of GMP certification. With excellent product quality and customer-first service concept, they have established a medical and health field. The brand image of "Furida" has created many well-known brands such as "Runshu", "Runjie", "Shipei", "Mingren", "Yilian", and "Dr. Aier". The products are sold to North America, the EU, Japan and South Korea. , Southeast Asia and more than 70 countries and regions.

In the future, Freda adheres to the corporate mission of "technology creates a healthy ecology", accelerates the reshaping of the value of "strategy, business, organization, and culture", and implements the "1234" high-quality innovation and development strategy, namely: consolidating the leading advantage of hyaluronic acid, Focus on the two main businesses, make the pharmaceutical sector special and expand the pharmaceutical sector, strengthen and optimize the cosmetic sector, promote the development of the "three modernizations", take the path of differentiated, ecological and internationalized development, implement the four major projects, and continue to promote R&D-driven, Talent-leading, brand-driven, and digital-enabled empowerment are committed to becoming an internationally renowned leading pharmaceutical and health enterprise that society trusts.